about
Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation.Risk Factors and Impact of Secondary Failure of Platelet Recovery After Allogeneic Stem Cell Transplantation.Graft-versus-host disease and survival after cord blood transplantation for acute leukemia: a comparison of Japanese versus White populationsComparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.Evaluation of the validity of preemptive therapy against cytomegalovirus disease based on antigenemia assay with a cutoff of 20 positive cells per two slides.Decision analysis for donor selection in stem cell transplantation-HLA-8/8 allele-matched unrelated donor vs HLA-1 AG mismatched related donorOutcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantationA HAMP promoter bioassay system for identifying chemical compounds that modulate hepcidin expression.Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation.Different effects of HLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemiaPre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment.Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations.High pretransplant hepcidin levels are associated with poor overall survival and delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation.Haploidentical transplantation for leukemia.Iron overload and allogeneic hematopoietic stem-cell transplantation.Impact of the presence of HLA 1-locus mismatch and the use of low-dose antithymocyte globulin in unrelated bone marrow transplantation.GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia.Role of reduced-intensity conditioning allogeneic hematopoietic cell transplantation in older patients with de novo acute myeloid leukemia.Acidic milieu augments the expression of hepcidin, the central regulator of iron homeostasis.Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation.A case-control study of bronchiolitis obliterans syndrome following allogeneic hematopoietic stem cell transplantation.Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes.Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria.Oncostatin M and leukemia inhibitory factor increase hepcidin expression in hepatoma cell lines.Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older.Economic evaluation of a preemptive treatment strategy for invasive fungal infection in neutropenic patients with hematological diseases.[Epstein-Barr virus-associated B cell lymphoproliferative disorder complicated in adult T-cell leukemia].Comparison of Outcomes of 8/8 and 7/8 Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Cord Blood Transplantation in Adults with Acute Leukemia.Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation.Unrelated cord blood transplantation vs. related transplantation with HLA 1-antigen mismatch in the GVH direction.Age influences post-graft-versus-host disease non-relapse mortality in adults with acute graft-versus-host disease of varying severity following allogeneic hematopoietic cell transplant.Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation.Impact of HLA allele mismatch on the clinical outcome in serologically matched related hematopoietic SCT.Changes in the clinical impact of high-risk human leukocyte antigen allele mismatch combinations on the outcome of unrelated bone marrow transplantation.Risk factors and organ involvement of chronic GVHD in Japan.Association of alcohol intake with the risk of malignant lymphoma and plasma cell myeloma in Japanese: a population-based cohort study (Japan Public Health Center-based Prospective Study).Impact of discontinuing fluoroquinolone prophylaxis on early mortality after allogeneic marrow or peripheral blood SCT with myeloablative conditioning.Association between obesity and the risk of malignant lymphoma in Japanese: a case-control study.Association of alcohol intake and smoking with malignant lymphoma risk in Japanese: a hospital-based case-control study at Aichi Cancer Center.Impact of the direction of HLA mismatch on transplantation outcomes in single unrelated cord blood transplantation.
P50
Q31026869-9C2CC1C4-66E8-4269-B778-C6DBDE30B38FQ33432975-9D342BC8-F6F9-4C31-8414-1D527B1407FFQ33810316-10F159DD-A8A3-4C9A-AC80-EA54A864E7C8Q33822026-DF50E4E2-CC2E-4D6E-B9E8-1B7BD6D3E255Q34989242-BC31B266-38EB-4351-B434-E7151D9D51BEQ35044982-EFA02818-097D-4045-B375-C0AA2E90DE8CQ35545424-32401E92-2E70-452F-BCD8-8BE57230A5F1Q35551400-7F930950-7CF4-4D7A-B73B-D4E5A8CC322DQ36319846-1EBA1B7C-47BD-4188-AB36-F527BB5D0A83Q36805898-EB153A5A-6291-43D5-8B15-701E89FD271CQ36983064-EAEEB6CA-9BA1-46C1-B8D4-50C7CBC33DBCQ37331218-752F2AA3-2F52-446A-8C69-62232F6FF196Q37609241-7106FD96-A3CD-4364-9E2D-99EA0194AB97Q37770075-88A90BFC-2FCC-4211-B691-4E47F4DF4DA0Q37842351-DB5F0BED-B3AE-4BB7-B5D0-96324B55D89EQ38675879-FF77AA24-86EA-4D0F-A9D1-75085C63E636Q38730402-DAC6A5B0-D5F4-4CE9-BDA3-827CFD4DE422Q39192183-92286F9F-439C-46AF-AC49-BB32C073EDCEQ39239032-C9C385C8-4AE6-403E-A224-D812CA7D29C0Q39283573-29BF7390-D50C-49A2-875E-3CC14B421E17Q39441064-30D7448E-FF6E-404D-AD46-C2183F0D7A80Q39522581-EA82169F-A40F-4603-935B-8DD8FA4CC3A0Q39763917-0BD419F6-F05A-4A0D-9E59-81F1F62FE126Q39774148-82B87D24-4CE9-42DF-8953-F11EE86AB30DQ39972636-CB5A1DD8-84EB-46BF-896A-7CC0FD682E5CQ40174281-A6990EC0-FEC7-41DB-959B-6228BC9D9A16Q40417831-0CE415CB-1D21-48EA-9193-5C562587DF01Q40421080-F2DD5FA7-F125-42CF-9D52-8570D38F87CBQ40542259-E2CAA0C3-B317-4602-93AB-6D0B83C2C6B5Q40848703-F1BCA906-1249-44DF-B7EF-66F290410A03Q41513936-602BF31D-597C-47E6-854C-2808461E4AD6Q41587535-8B338A0B-E41B-41FF-8BC2-0DE83A52236BQ42207198-2017FB17-624F-4895-A938-A218F6DA3AD1Q42233224-D8818712-0AE3-4454-928C-B2A4D43EBEEBQ42246123-6D4491FC-908D-4BAF-91E5-361DCEBFC02FQ43189594-6BFDBBE0-D86A-4CB0-B3D4-AC014FBACFFEQ43228480-8DA87854-56FE-476D-87D1-8AA48477989AQ43263387-70AC9600-C34A-47C8-81E9-4D5F52E22ABDQ43282317-B7F36E0F-ED29-4DDB-9473-2B8CE6542282Q43880929-70B5EB1D-8D2D-43A7-B34C-A67BBFB22EB6
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Junya Kanda
@ast
Junya Kanda
@en
Junya Kanda
@es
Junya Kanda
@sl
type
label
Junya Kanda
@ast
Junya Kanda
@en
Junya Kanda
@es
Junya Kanda
@sl
prefLabel
Junya Kanda
@ast
Junya Kanda
@en
Junya Kanda
@es
Junya Kanda
@sl
P106
P31
P496
0000-0002-6704-3633